Boston Scientific ($BSX) gained a CE mark for its Vercise deep brain stimulation system as a Parkinson's disease treatment. It uses electrical signals on specific areas of the brain to address Parkinson's symptoms. The Natick, MA-based device company bills its system as the first on the commercial market able to use multiple independent current control. Vercise could reach an enormous amount of Parkinson's patients; as many as 6.3 million people globally, according to data Boston Scientific cites from the European Parkinson's Disease Association. Release